Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Peripheral Vasodilator Drugs Market?

In the past few years, the market size of peripheral vasodilator drugs has witnessed substantial growth. The market is projected to grow from $6.27 billion in 2024 to $6.61 billion in 2025, with a compound annual growth rate (CAGR) of 5.3%. The prominent growth during the historic period could be credited to the shift towards less invasive surgical methods, growing demand for minimally invasive structural heart devices, continual training and educational programs for healthcare professionals, increased healthcare spending, and a rising patient preference for non-surgical or minimal-invasive treatment alternatives.

In the coming years, the market for peripheral vasodilator drugs is projected to experience robust growth, with its value expected to reach $8.18 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.5%. This anticipated growth in the forecast period can be traced back to factors such as a rise in the elderly population, heightened awareness about cardiovascular health, the introduction of screening programs, beneficial reimbursement policies for structural heart procedures, and prompt regulatory sanctions for new structural heart devices. Some major trends to look out for during the forecast period are enhanced collaboration, practical evidence, gene therapy, preventive measures, and value-based healthcare.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16508&type=smp

What Underlying Factors Are Supporting The Peripheral Vasodilator Drugs Market Growth?

The peripheral vasodilator drug market is expected to witness expansion due to the rising occurrence of cardiovascular diseases. Cardiovascular diseases (CVDs), which encompass a range of disorders affecting the heart and blood vessels, are often precipitated by atherosclerosis, culminating in conditions like heart attacks, strokes, hypertension, and heart failure. The onset of such diseases is largely attributed to factors such as inactive lifestyles, unhealthy eating habits, aging populace, escalating obesity rates, and associated health issues like diabetes and hypertension. Peripheral vasodilators play a significant role in combating cardiovascular diseases by enhancing blood flow, lowering blood pressure, reducing the strain on the heart, and mitigating symptoms of conditions like peripheral arterial disease. For example, data from the Australian Institute of Health and Welfare, a governmental agency based in Australia, indicated that in June 2024 certificate-validated deaths due to coronary heart disease (CHD) escalated to 14,100 in 2021, and rose further to 14,900 in 2022. As such, the surging prevalence of cardiovascular diseases is fostering the growth of the peripheral vasodilator drug market.

Which Segments Define The Structure Of The Peripheral Vasodilator Drugs Market?

The peripheral vasodilator drugs market covered in this report is segmented –

1) By Drug Type: Calcium Channel Blockers, Direct-Acting Vasodilators, Alpha-Adrenergic Blockers, Potassium Channel Activators, Nitrates, Other Types

2) By Indication: Hypertension, Angina, Heart Failure, Other Indications

3) By Application: Hospital, Retail Pharmacies, Other Applications

Subsegments:

1) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

2) By Direct-Acting Vasodilators: Hydralazine, Minoxidil, Nitroprusside

3) By Alpha-Adrenergic Blockers: Prazosin, Doxazosin, Terazosin

4) By Potassium Channel Activators: Nicorandil, Diazoxide

5) By Nitrates: Nitroglycerin, Isosorbide Dinitrate, Isosorbide Mononitrate

6) By Other Types: Phosphodiesterase Inhibitors, Endothelin Receptor Antagonists

What Strategic Shifts And Innovations Are Influencing The Peripheral Vasodilator Drugs Market?

Leading businesses in the market of peripheral vasodilator drugs are investing in the creation of triple-drug combination therapies with the aim to bolster treatment success rates and grow their presence in the arena of cardiovascular therapeutics. This form of therapy, a hypertensive multiple-drug combination treatment, is for patients who have not seen sufficient reductions in blood pressure from two-drug treatments or cannot withstand combinations that include diuretics. To illustrate, Ajanta Pharma Limited, a pharmaceutical organization based in India with a focus on cardiology, launched Met XL AMT, an innovative triple-drug combination therapy for managing hypertension, in August 2023. This therapy is an FDC (fixed-dose combination) that consists of three hypertension treatment agents, namely Telmisartan, Amlodipine, and Metoprolol, which work synergistically to lessen blood pressure by easing tension in the blood vessels; this is a trait of peripheral vasodilators. This particular medication is officially recognized by DCGI for the management of immoderate blood pressure in tandem with stable coronary artery disease, which establishes it as the first ever fixed-dose combination (FDC) of metoprolol succinate (extended-release) 50 mg, amlodipine 5 mg, and telmisartan 40 mg on a global scale.

Who Are The Most Influential Companies In The Peripheral Vasodilator Drugs Market?

Major companies operating in the peripheral vasodilator drugs market are Pfizer Inc., Bayer AG, Sanofi S.A., Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company, Gilead Sciences Inc, Amgen Inc, Boehringer Ingelheim International GmbH, Merck & Co, Viatris Inc., Baxter, Teva Pharmaceutical Industries, Astellas Pharma, Daiichi Sankyo Company, Limited, Sun Pharmaceutical Industries, Mitsubishi Tanabe Pharma, Cipla Limited, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals, Ipca Laboratories, Alembic Pharmaceuticals

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/peripheral-vasodilator-drugs-global-market-report

Which Region Is Forecasted To Lead The Peripheral Vasodilator Drugs Market In The Coming Years?

North America was the largest region in the peripheral vasodilator drugs market in 2024. The regions covered in the peripheral vasodilator drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=16508&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model